Sigma Healthcare (ASX:SIG) raised its fiscal 2025 normalized earnings before interest and tax guidance to a range of AU$64 to AU$70 million, up from the previous guidance of AU$50 to AU$60 million, according to a Friday filing with the Australian bourse.
The increase follows strong performance, particularly from the Chemist Warehouse supply contract that started on July 1, 2024, the filing said.
Statutory net profit after tax for the fiscal year will be "significantly" impacted by non-recurring merger costs, including changes to performance rights, subject to audit completion, the filing added.
The company's shares rose past 5% in recent Friday trade.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。